OpenAI launches GPT-Rosalind, a frontier AI model purpose-built for life sciences that outperforms human experts above the 95th percentile on RNA sequence-to-function tasks, beats competitors on key benchmarks, and is now available in research preview for U.S. Enterprise customers through partnerships with Amgen, Moderna, and the Allen Institute.
AWS launches Amazon Bio Discovery, an AI-powered platform that designed nearly 300,000 novel antibody molecules in collaboration with Memorial Sloan Kettering Cancer Center, slashing drug discovery timelines from up to a year down to just weeks.
AI is going deeply personal this week: Utah launches a pilot letting AI renew psychiatric prescriptions for just $19/month, OpenAI secures a record $122 billion funding round at an $852 billion valuation, and thousands of workers worldwide are filming their daily chores to train the next generation of humanoid robots.
Anthropic acquires stealth AI biotech startup Coefficient Bio in a $400 million stock deal, bringing the 10-person team behind an AI-driven drug discovery platform into its health and life sciences division, accelerating the company's growing push into healthcare.
Eli Lilly signs a landmark $2.75 billion deal with AI drug pioneer Insilico Medicine, offering $115 million upfront to fast-track AI-generated drugs across multiple disease areas into global markets.
NVIDIA CEO Jensen Huang declares AI infrastructure the largest buildout in human history, requiring trillions in investment across a five-layer stack of energy, chips, infrastructure, models, and applications, as open source models accelerate adoption and industries from drug discovery to robotics begin generating measurable economic value.
MIT and Microsoft researchers are using AI to design nanoparticle sensors that detect early-stage cancer through a simple urine test, with scientists now working to develop an at-home diagnostic kit capable of identifying up to 30 types of cancer.
AI adoption in healthcare is surging, with 70% of organizations now using the technology in 2026, delivering powerful financial returns as 85% of executives report increased revenue and 80% cite reduced costs, fueling massive budget increases across the industry.
Isomorphic Labs unleashes IsoDDE, a groundbreaking AI drug-discovery engine that outperforms open-source rivals in predicting drug-protein interactions, but scientists are raising concerns as the powerful DeepMind spin-off keeps its technology fully proprietary, blocking the broader research community from replicating or building on its breakthroughs.
A former Anthropic Claude product leader joins Google as VP of Product for Vertex AI and Agents, bringing insider AI expertise to accelerate enterprise adoption while warning that trust barriers around accountability are slowing deployment, and advising companies to start with narrow, low-risk workflows before scaling up.